Neurocrine Biosciences, Inc.

Agouron Pharmaceuticals, Inc.

Michael Allen Ouellette

Robert Michael Hughes

Onorato Campopiano

Laszlo R Treiber

Donald Nicholas Hettinger

Yuxin Zhao

Peng Wang

Donald J Gallagher

Shine K Chou

Kanyin E Zhang

Jayaram Kasturi Srirangam

Barbara C M Potts

Anthony R Tibbetts

The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof.

Processes for the preparation of uracil derivatives

The present invention relates to processes and intermediates for preparing Gonadotropin-Releasing Hormone (GnRH) receptor antagonists of structure (VI); and stereoisomers and pharmaceutically acceptable salts thereof. 

Bag for powered ice auger

Metabolites of a matrix metalloproteinase inhibitor prinomastat and their synthesis. These metabolites are: (3S)-N-hydroxy-4-(4-((1-oxy-pyrid-4-yl)oxy)benzenesulfonyl)-2,2-dimethyl-tetrahydro-2H-1,4-thiazine-3-carboxamide (M6); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(1-oxy-pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M7); (3S)-2,2-dimethyl-4-[4-(1-oxypyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M8); (3S)-2,2-dimethyl-1,1-dioxo-4-[4-(pyridin-4-yloxy)-benzenesulfonyl]-thiomorpholine-3-carboxylic acid amide (M2); and (3S)-2,2-dimethyl-4-[4-(pyridin-4yloxy)-benzenesulfonyl)-thiomorphpline-3-carboxylic acid amide (M3).

Metabolites of prinomastat and their synthesis

Growing community of inventors

San Diego, CA, United States of America

Michael Allen Ouellette